CClinicalTrials.gg
Sign In
Not yet recruitingNCT05126888Updated Apr 21, 2026

SCI-110 in the Treatment of Tourette Syndrome

A Phase 2 interventional study of SCI-110 and Placebo in Tourette Syndrome, sponsored by Neurothera Labs Inc.. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Neurothera Labs Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.

Read the detailed description

It is believed that SCI-110 will be a valuable treatment option, especially for t those subjects with TS, who do not benefit from or do not tolerate first-line treatment with antipsychotics. Since there is evidence that currently available CBM improves not only tics, but also psychiatric comorbidities, SCI-110 might be even more beneficial to improve a broader spectrum of symptoms resulting in both improved quality of life and decreased disease related costs. Moreover, PEA was shown to minimize AEs associated with cannabinoids use and to reduce their required effective dose (data not published). Hence, the use of SCI-110 is expected to show a therapeutic effect superior to currently available CBMs.

It can be assumed that AEs in TS subjects do not differ from AEs described in other groups of subjects treated with medicinal cannabis and/or cannabinoids. In general, cannabinoids are considered as well tolerated.

02

Conditions studied

  • Tourette Syndrome

Browse trials for

03

In context

Tourette Syndrome

220 studies on the registry are indexed under Tourette Syndrome; 37 are open to participants now.

This study's planned enrollment of 164 is above the median of 34 across 166 interventional studies indexed under Tourette Syndrome.

Browse Tourette Syndrome studies →

Lead sponsor

This is the only study on the registry with Neurothera Labs Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Tourette syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
  2. Male and female subjects with an age between ≥18 and ≤65 years
  3. Total tic score (TTS) of the revised Yale Global Tic Severity Scale (YGTSS-R) >14
  4. Clinical Global Impression-Severity Score (CGI-S) ≥4
  5. Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study
  6. Signed written informed consent and willingness to comply with treatment and follow-up procedures
  7. Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study

  8. Women of child-bearing potential must have a negative pregnancy test (e.g., urine human chorionic gonadotropin [hCG]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year as when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Women without childbearing potential may enter this study. Women without childbearing potential defined as follows:

    • at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
    • hysterectomy or uterine agenesis or
    • ≥ 50 years and in postmenopausal state ≥ 1 year or
    • \< 50 years and in postmenopausal state ≥ 1 year with urine FSH > 40 IU/l and urine oestrogen \< 30 ng/l, or serum follicle stimulating hormone (FSH) in the post-menopausal range or a negative oestrogen test.
  9. Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study

Exclusion criteria

Exclusion Criteria:

  1. Comorbid obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety disorder when unstable or in need of an initial adjustment for a therapy-according to the investigator's judgment
  2. Presence of severe psychiatric conditions such as developmental disability, psychotic illness and bipolar disorder- according to the investigator's judgment
  3. Ongoing behavioural treatment for tics
  4. History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder
  5. Current clinical diagnosis of substance abuse or dependence
  6. History of cannabis dependence
  7. Secondary and other chronic tic disorders or other significant neurological disorders
  8. Known severe cardiac diseases, known severe cardiovascular diseases, known positivity for human immunodeficiency virus (HIV), hepatitis C, hepatitis B, or other severe hepatic and renal disorders by history
  9. Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence)
  10. Use of cannabis or cannabinoid-based medicine (CBM) in the 30-day period prior to study entry and/or positive delta-9-tetrahydrocannabinol (THC) urine test at baseline
  11. Positive urine ß-HCG pregnancy test
  12. Pregnant or breast-feeding women
  13. Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study
  14. Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and ingredients of study medication (e.g., cannabis, cannabinoids, or sesame oil)
  15. Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject
  16. Subjects who are employees of the sponsor or employees or close relatives of the investigator
  17. Subjects with active suicidal ideation and behaviour (SI/B) according to the Columbia-Suicide Severity Rating Scale (C-SSRS) and/or subjects that have attempted suicide in the past.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    SCI-110

    Cannabinoid-based medication consisting of Dronabinol and PEA

    Drug: SCI-110

  • Placebo comparator
    Dronabinol

    Placebo matched in taste, odour and appearance to SCI-110

    Other: Placebo

Interventions

  • DrugSCI-110

    SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.

  • OtherPlacebo

    Pill that matches in taste, odour and appearance to SCI-110 active pills

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)

    Absolute change from baseline in revised version of YGTSS-R-TTS as a continuous endpoint at week 12 of the respective treatment period. The Global Severity Score has a range of 0- 100. A higher score on the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.

    Time frame: At baseline and 12 weeks after start of treatment in both arms.

Secondary outcomes

  1. Percent reduction in Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS) of at least 20%

    Response to treatment according to YGTSS-R-TTS of at least 20% reduction (compared to baseline) The responder criterion defined as a more severe Tic, or a greater impact the Tic has on the person's life The Global Severity Score has a range of 0- 100. A higher score the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.

    Time frame: At baseline and 12 weeks after start of treatment in both arms.

  2. Percent reduction in Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS) of at least 30%, 35% and 50%

    Response to treatment according to YGTSS-R-TTS responder criterion, defined as a percent reduction in YGTSS-R-TTS of at least 30%, 35% and 50% (compared to baseline) The Global Severity Score has a range of 0- 100. A higher score on the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.

    Time frame: Week 12 of each treatment period (visit 8 and 15).

  3. Absolute change from baseline of YGTSS-R Total Score

    Absolute change from baseline of YGTSS-R Total Score, the corresponding subdomain motor and phonic total tic scores, the YGTSS-R Impairment Score, as well as of the combination of the total tic score and the impairment score (YGTSS-R-GS (= YGTSS-R-TTS + YGTSS-R-impairment score).

    Time frame: At baseline and 12 weeks after start of treatment in both arms.

  4. Percent change from baseline of YGTSS-R Total Score

    Percent change from baseline of YGTSS-R Total Score, the corresponding subdomain motor and phonic total tic scores, the YGTSS-R Impairment Score, as well as of the combination of the total tic score and the impairment score (YGTSS-R-GS (= YGTSS-R-TTS + YGTSS-R-impairment score).

    Time frame: At baseline and 12 weeks after start of treatment in both arms.

  5. Clinical Global Impression-Improvement Score (CGI-I)

    Absolute values of the Clinical Global Impression-Improvement Score (CGI-I). CGI is a 7 point scale that ranges from 1 Very much improved to 7 Very much worse

    Time frame: 24 weeks

  6. Clinical Global Impression-Severity Score (CGI-S) Absolute result

    Absolute change from baseline of Clinical Global Impression-Severity Score (CGI-S). CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. The range is from 1 Normal, not at all ill to 7 Among the most extremely ill patients

    Time frame: 24 weeks

  7. Clinical Global Impression-Severity Score (CGI-S) Percent result

    Percent change from baseline of Clinical Global Impression-Severity Score (CGI-S). CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. The range is from 1 Normal, not at all ill to 7 Among the most extremely ill patients

    Time frame: 24 weeks

  8. Total Pre-monitory Urge for Tics Scale (PUTS) Absolute Score

    Absolute change from baseline of the total Pre-monitory Urge for Tics Scale (PUTS) Score. The range of the test is between 9 - 36. A higher score on the scale indicates an extremely high intensity with probable severe impairment.

    Time frame: 24 weeks

  9. Total Pre-monitory Urge for Tics Scale (PUTS) Percent Score

    Percent change from baseline of the total Pre-monitory Urge for Tics Scale (PUTS) Score. The range of the test is between 9 - 36. A higher score on the scale indicates an extremely high intensity with probable severe impairment.

    Time frame: 24 weeks

  10. Adult Tic Questionnaire (ATQ) Percent Score

    Percent change from baseline of the total Adult Tic Questionnaire (ATQ) Score. The Adult Tic Questionnaire (ATQ) Score has a range of 0- 50. A higher score on all scales suggests a more severe Tic, or a greater impact the Tic has on the person's life.

    Time frame: 24 weeks

  11. Adult Tic Questionnaire (ATQ) Absolute Score

    The absolute change from baseline of the total Adult Tic Questionnaire (ATQ) Score. The Adult Tic Questionnaire (ATQ) Score has a range of 0- 50. A higher score on all scales suggests a more severe Tic, or a greater impact the Tic has on the person's life.

    Time frame: 24 weeks

  12. Changes in Beck Depression Inventory (BDI-II) Percent score.

    Percent change from baseline of the Beck Depression Inventory (BDI-II) total score The questionnaire contains about 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. 0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression

    Time frame: 24 weeks

  13. Changes in Beck Depression Inventory (BDI-II) absolute score.

    Absolute change from baseline of the Beck Depression Inventory (BDI-II) total score The questionnaire contains about 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. 0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression

    Time frame: 24 weeks

  14. Changes in Yale-Brown Obsessive Compulsive Scale (Y BOCS) absolute score

    Absolute change from baseline of the Yale-Brown Obsessive Compulsive Scale (Y BOCS) Total scores on the measure range from 0 to 40, with a score of 0-7 indicating subclinical symptoms, 8-15 mild symptoms, 16-23 moderate symptoms, 24-31 severe symptoms and 32-40 extreme symptoms.

    Time frame: 24 weeks

  15. Changes in Yale-Brown Obsessive Compulsive Scale (Y BOCS) Percent score

    Percent change from baseline of the Yale-Brown Obsessive Compulsive Scale (Y BOCS) score. Total scores on the measure range from 0 to 40, with a score of 0-7 indicating subclinical symptoms, 8-15 mild symptoms, 16-23 moderate symptoms, 24-31 severe symptoms and 32-40 extreme symptoms.

    Time frame: 24 weeks

  16. Changes in Obsessive-compulsive disorder (OCD) severity Absolute score

    Absolute change from baseline of the total Obsessive-compulsive disorder (OCD) severity score. The range of the test is between 8-15 = Mild OCD; 16-23 = Moderate OCD; 24-31= Severe OCD; 32-40 = Extreme OCD

    Time frame: 24 weeks

  17. Changes in Obsessive-compulsive disorder (OCD) severity Percent score

    Percent change from baseline of the total Obsessive-compulsive disorder (OCD) severity score. The range of the test is between 8-15 = Mild OCD; 16-23 = Moderate OCD; 24-31= Severe OCD; 32-40 = Extreme OCD

    Time frame: 24 weeks

  18. Changes in Conners' Adult ADHD Rating Scale (CAARS) Absolute score.

    Absolute change from baseline of the Conners' Adult ADHD Rating Scale (CAARS) score. When total score is less than 60 there is no indication of ADHD. A score higher than 60 may indicate ADHD. And a total score higher than 70 means ADHD with more serious symptoms.

    Time frame: 24 weeks

  19. Changes in Conners' Adult ADHD Rating Scale (CAARS) Percent score

    Percent change from baseline of the Conners' Adult ADHD Rating Scale (CAARS) score When total score is less than 60 there is no indication of ADHD. A score higher than 60 may indicate ADHD. And a total score higher than 70 means ADHD with more serious symptoms.

    Time frame: 24 weeks

  20. Changes in Beck Anxiety Inventory (BAI) Absolute scores

    Absolute and percent change from baseline of the Beck Anxiety Inventory (BAI) The BAI assessments contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms. The standardized cutoffs are: 0-7: Minimal, 8-15: Mild, 16-25: Moderate and 26-63: Severe

    Time frame: 24 weeks

  21. Changes in Beck Anxiety Inventory (BAI) percent scores

    Percent change from baseline of the Beck Anxiety Inventory (BAI) score. The BAI assessments contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms. The standardized cutoffs are: 0-7: Minimal, 8-15: Mild, 16-25: Moderate and 26-63: Severe

    Time frame: 24 weeks

  22. Changes in Beck Depression Inventory (BDI) Absolute score

    Absolute change from baseline of the total BDI score. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows: 0-9: indicates minimal depression, 10-18: indicates mild depression, 19-29: indicates moderate depression, 30-63: indicates severe depression. Higher total scores indicate more severe depression

    Time frame: 24 weeks

  23. Changes in Beck Depression Inventory (BDI) percent score

    Percent change from baseline of the total BDI score. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows: 0-9: indicates minimal depression, 10-18: indicates mild depression, 19-29: indicates moderate depression, 30-63: indicates severe depression. Higher total scores indicate more severe depression

    Time frame: 24 weeks

  24. Changes in Rage Attacks Questionnaire (RAQ-R) Absolute scores

    Absolute change from baseline of the Rage Attacks Questionnaire (RAQ-R) score. The RAQ-R assessments contains 22 questions, each answer being scored on a scale value of 0 (not at all) to 4 (Very powerful, very common). Higher total scores indicate more severe Rage Attacks.

    Time frame: 24 weeks

  25. Changes in Rage Attacks Questionnaire (RAQ-R) percent scores

    Percent change from baseline of the Rage Attacks Questionnaire (RAQ-R) score. The RAQ-R assessments contains 22 questions, each answer being scored on a scale value of 0 (not at all) to 4 (Very powerful, very common). Higher total scores indicate more severe Rage Attacks.

    Time frame: 24 weeks

  26. Changes in Pittsburgh Sleep Quality Index (PSQI) Absolute scores

    Absolute change from baseline of the Pittsburgh Sleep Quality Index (PSQI) global score. PSQI Consisting of 19 items, Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.

    Time frame: 24 weeks

  27. Changes in Pittsburgh Sleep Quality Index (PSQI) Percent scores

    Percent change from baseline of the Pittsburgh Sleep Quality Index (PSQI) global score. PSQI Consisting of 19 items, Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.

    Time frame: 24 weeks

  28. Changes to the Tourette Syndrome-Quality of Life Scale (GTS-QoL) score

    Changes from baseline of Tourette Syndrome-Quality of Life Scale (GTS-QoL). GTS-QoL is a 27-item, self-report questionnaire that assesses HR-QoL in young patients with tic disorders, encompassing 4 areas of HR-QoL: psychological, physical/activities of daily living, obsessive-compulsive, and cognitive domains. Each item is rated on a 5-point Likert-type scale and higher scores indicate worse HR-QoL. The instrument includes a Visual Analogue Scale used to express the extent of self-satisfaction about life (higher scores indicate higher satisfaction)

    Time frame: 24 weeks

  29. Changes to the 12-item short-form Health Survey (SF-12) score

    Changes from baseline of 12-item short-form Health Survey (SF-12). Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: 24 weeks

Other outcomes

  1. Number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs

    Number of adverse events (AEs), number and rate of patients affected by AEs, Serious Adverse Events (SAE), Suspected Unexpected Serious Adverse reactions (SUSAR) /Adverse Drug Reaction (ADR), Adverse Events of Special Interest (AESI) and AEs leading to withdrawal at each visit.

    Time frame: 24 weeks

  2. Absolute values of vital sign blood pressure at each visit and change from baseline.

    Absolute values of vital sign blood pressure at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.

    Time frame: 24 weeks

  3. Absolute values of vital sign heart rate at each visit and change from baseline.

    Absolute values of vital sign heart rate at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.

    Time frame: 24 weeks

  4. 2.3. Suicide risk assessment measured by the Columbia-Suicide Severity Rating Scale (CSSRS)

    Suicide risk assessment measured by the Columbia-Suicide Severity Rating Scale (CSSRS) and change from baseline for each on-site visit.

    Time frame: Through out the study

07

Study locations

3 sites
  • Yale Child Study Center - NIHB 205
    New Haven, Connecticut 06519, United States
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Neurological Institute, Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05126888
Lead sponsor
Neurothera Labs Inc.
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Jun 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Apr 21, 2026

Study contacts

Adi Zuloff-Shani, PhD
Contact
adi@scisparc.com
972-3-7175777
Kirsten R Müller-Vahl, PhD. MD
principal investigator · Hannover Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tourette Syndrome→

Start the discussion